Important note

This AI stock analysis for 23andMe is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

23andMe - AI Stock Analysis

Analysis generated November 21, 2024

23andMe, headquartered in Sunnyvale, California, is a genomics and biotechnology company primarily known for offering direct-to-consumer genetic testing services. Founded in 2006, the company has become a significant player in personalized health and ancestry information via genetic data. Their model empowers consumers with access to their genetic information, promoting greater health awareness and fostering interest in ancestry-related information.

Fundamental Analysis

Revenue for the last quarter stood at $44M, marking a 9.05% increase from the previous quarter, which is a positive indicator as it suggests growth in the short term. However, compared to the same quarter last year, there is a decrease of 11.86%, a red flag that the company may be struggling to maintain its previous revenue levels.

Net income for the last quarter was $59M. This figure is up by 14.84% from the previous quarter, showing robust short-term growth. Importantly, compared to the same quarter last year, net income has increased by 21.48%, indicating strong year-over-year improvement, which could suggest effective cost management or improved operational efficiency.

EBITDA for the last quarter also painted a favorable picture at $57M. This is an increase of 15.83% from the previous quarter and represents a year-over-year increase of 20.86%. Consistent growth in EBITDA underscores the company's operational strength and its ability to generate cash flow from its core operations.

Technical Analysis

The current stock price is $3.30. This represents a significant decrease of 32.52% compared to a month ago, raising short-term concerns about investor sentiment and market conditions. Moreover, the stock price has declined by 81.23% compared to a year ago, signaling longer-term concerns that must be addressed.

Additionally, the trend is bearish, with the current Simple Moving Average (SMA10) at 3.45, down from the previous SMA10 of 3.58. This suggests potential downward price movement in the near term. The Relative Strength Index (RSI) is at 59.7, indicating a neutral condition where neither overbought nor oversold pressures dominate.

Alternative Data Analysis

Alternative data metrics might further inform our understanding of 23andMe's current health. According to the most popular job boards, the company has just 4 open positions, a number that has declined by 86% in the last couple of months. This suggests efforts to cut costs or streamline operations.

Employee sentiment seems low, with only 15% of employees having a positive outlook on the company's future. This factor has declined by 29% recently, signaling internal challenges or reduced morale.

Customer acquisition metrics reveal an estimated 6.6M visitors to their webpage, with no significant trend changes in the past months. The company sees 840 mobile app downloads daily, though these downloads have decreased by 21% in the last couple of months. This downward trend could indicate a loss in customer interest and engagement.

Regarding customer engagement, 23andMe has 140,000 Instagram followers and 90,000 Twitter followers. Both metrics have either remained static or declined slightly, indicating potential stagnation in public interest and engagement.

Last but certainly not least, AltIndex’s AI score—a composite measure integrating fundamental, technical, and alternative data—provides a score of 31, interpreted as a strong sell signal.

Conclusion and Recommendation

23andMe exhibits a mixed financial outlook rooted in its fundamental, technical, and alternative data analyses. While there are signs of short-term improvements in revenue, net income, and EBITDA, the company faces long-term challenges, highlighted by significant stock price declines and adverse employee sentiment figures. Customer engagement and acquisition metrics further caution against optimism, painting a comprehensive picture of concern over future growth prospects.

Given these observations, a cautious approach is advised. Potential investors should carefully evaluate whether the company can overcome its current challenges before taking action.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.